Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Literature DB >> 17558427

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Myron M Levine¹, Karen L Kotloff, Eileen M Barry, Marcela F Pasetti, Marcelo B Sztein.

Abstract

More than 50 years of research has yielded numerous Shigella vaccine candidates that have exemplified both the promise of vaccine-induced prevention of shigellosis and the impediments to developing a safe and effective vaccine for widespread use, a goal that has yet to be attained. This Review discusses the most advanced strategies for Shigella vaccine development, the immune responses that are elicited following disease or vaccination, the factors that have accelerated or impeded Shigella vaccine development and our ideas for the way forward.

Entities: Disease

Mesh：

Substances：

Year: 2007 PMID： 17558427 PMCID： PMC3771495 DOI： 10.1038/nrmicro1662

Source DB: PubMed Journal: Nat Rev Microbiol ISSN： 1740-1526 Impact factor: 60.633

124 in total

1. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

Authors: Edwin V Oaks; K Ross Turbyfill
Journal: Vaccine Date: 2005-12-05 Impact factor: 3.641

2. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors: K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal: Infect Immun Date: 1992-06 Impact factor: 3.441

3. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors: L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal: Infect Immun Date: 2001-07 Impact factor: 3.441

4. Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.

Authors: M M Levine; H L Dupont; E J Gangarosa; R B Hornick; M J Snyder; J P Libonati; K Glaser; S B Formal
Journal: Am J Epidemiol Date: 1972-07 Impact factor: 4.897

5. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors: D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal: J Infect Dis Date: 1988-05 Impact factor: 5.226

6. Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati).

Authors: T Meitert; E Pencu; L Ciudin; M Tonciu
Journal: Arch Roum Pathol Exp Microbiol Date: 1984 Jul-Dec

7. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.

Authors: L Van de Verg; D A Herrington; J R Murphy; S S Wasserman; S B Formal; M M Levine
Journal: Infect Immun Date: 1990-06 Impact factor: 3.441

8. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.

Authors: Armelle Phalipon; Corina Costachel; Cyrille Grandjean; Audrey Thuizat; Catherine Guerreiro; Myriam Tanguy; Farida Nato; Brigitte Vulliez-Le Normand; Frédéric Bélot; Karen Wright; Véronique Marcel-Peyre; Philippe J Sansonetti; Laurence A Mulard
Journal: J Immunol Date: 2006-02-01 Impact factor: 5.422

9. Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri.

Authors: M M Levine; W E Woodward; S B Formal; P Gemski; H L DuPont; R B Hornick; M J Snyder
Journal: J Infect Dis Date: 1977-10 Impact factor: 5.226

10. Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease.

Authors: D Islam; P K Bardhan; A A Lindberg; B Christensson
Journal: Infect Immun Date: 1995-08 Impact factor: 3.441

131 in total

Review 1. Secretory IgA: arresting microbial pathogens at epithelial borders.

Authors: Nicholas J Mantis; Stephen J Forbes
Journal: Immunol Invest Date: 2010 Impact factor: 3.657

Review 2. Shigella: a model of virulence regulation in vivo.

Authors: Benoit Marteyn; Anastasia Gazi; Philippe Sansonetti
Journal: Gut Microbes Date: 2012-03-01

Review 3. Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings.

Authors: Natalie G Exum; Nora Pisanic; Douglas A Granger; Kellogg J Schwab; Barbara Detrick; Margaret Kosek; Andrey I Egorov; Shannon M Griffin; Christopher D Heaney
Journal: Curr Environ Health Rep Date: 2016-09

Review 4. Enteric infections, diarrhea, and their impact on function and development.

Authors: William A Petri; Mark Miller; Henry J Binder; Myron M Levine; Rebecca Dillingham; Richard L Guerrant
Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808

5. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.

Authors: BreOnna C DeLaine; Tao Wu; Christen L Grassel; Avital Shimanovich; Marcela F Pasetti; Myron M Levine; Eileen M Barry
Journal: Pathog Dis Date: 2016-04-21 Impact factor: 3.166

Review 6. Recent advances in understanding enteric pathogenic Escherichia coli.

Authors: Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal: Clin Microbiol Rev Date: 2013-10 Impact factor: 26.132

7. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

Authors: J Wayne Conlan; Hua Shen; Igor Golovliov; Carl Zingmark; Petra C F Oyston; Wangxue Chen; Robert V House; Anders Sjöstedt
Journal: Vaccine Date: 2009-12-16 Impact factor: 3.641

8. Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneri.

Authors: Changyun Ye; Ruiting Lan; Shengli Xia; Jin Zhang; Qiangzheng Sun; Shaomin Zhang; Huaiqi Jing; Lei Wang; Zhenjun Li; Zhemin Zhou; Ailan Zhao; Zhigang Cui; Jingjing Cao; Dong Jin; Lili Huang; Yiting Wang; Xia Luo; Xuemei Bai; Yan Wang; Ping Wang; Qiang Xu; Jianguo Xu
Journal: J Clin Microbiol Date: 2009-12-02 Impact factor: 5.948

9. Comparison of two label-free global quantitation methods, APEX and 2D gel electrophoresis, applied to the Shigella dysenteriae proteome.

Authors: Srilatha Kuntumalla; John C Braisted; Shih-Ting Huang; Prashanth P Parmar; David J Clark; Hamid Alami; Quanshun Zhang; Arthur Donohue-Rolfe; Saul Tzipori; Robert D Fleischmann; Scott N Peterson; Rembert Pieper
Journal: Proteome Sci Date: 2009-06-29 Impact factor: 2.480

10. A unified approach to molecular epidemiology investigations: tools and patterns in California as a case study for endemic shigellosis.

Authors: Sawsan Al-Nimri; Woutrina A Miller; Barbara A Byrne; Gerry Guibert; Lily Chen
Journal: BMC Infect Dis Date: 2009-11-24 Impact factor: 3.090